The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?
Crossref DOI link: https://doi.org/10.1186/s12967-017-1334-1
Published Online: 2017-12-15
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Omarjee, Loukman http://orcid.org/0000-0001-7766-396X
Jaquinandi, Vincent
Mahe, Guillaume
